The board of directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the incentive program

The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) on 26 April
2012 resolved - for the purpose of ensuring that the Company can fulfill its
commitments under the long-term incentive program resolved by the Annual General
Meeting - on a directed share issue of no more than 1,655,136 redeemable- and
convertible class C shares.

The General Meeting also resolved to authorize the board of directors to resolve
on the repurchase of all issued class C shares by an offer directed to all
holders of class C shares. Repurchase under this authorization may be made on
one or several occasions until the Annual General Meeting in 2013 and at a price
to no less than 100 per cent and no more than 105 per cent of the quotient value
of the share (approximately SEK 0.55).

The board of directors has resolved to exercise the repurchase authorization for
the said purpose by repurchasing of all issued class C shares against payment of
100 per cent of the quotient value of the share, corresponding to approximately
SEK 0.55 per share. Repurchase of the class C shares may be effected during the
period 20 July - 26 September 2012.

The company currently holds 2,753,124 own class C shares. Subsequently to the
effected repurchase of class C shares above, the number of own class C shares
will amount to 4,408,260.

The class C shares will, following the repurchase, be converted to common shares
in the number that is required to ensure delivery under the incentive program.

For further information, please contact:
-Åsa Stenqvist, Head of Communications and IR at +46 8 697 21 88


Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing
innovative therapies and services to improve the lives of rare disease patients.
The product portfolio is primarily focused on Inflammation and on Genetics and
Metabolism, and three late stage biological development projects within
hemophilia and neonatology. Sobi also has a portfolio of more than 40 products
which it commercializes on behalf of specialty and rare disease partners
companies. In 2011, Sobi had revenues of SEK 1.9 billion and around 500
employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More
information is available at www.sobi.com.


The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on 14 September 2012 at 8.30 a.m. CET.